Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971986 | 0.91 | KMT2A (0.36) | KMT2AMEN1BLMGAAPOLB | |
| SCHEMBL17640293 | 0.88 | MAPT (0.38) | KMT2AMEN1BLMGAAPOLB | |
| SCHEMBL20971892 | 0.85 | MAPT (0.38) | KMT2AMEN1BLMGAAPOLB | |
| SCHEMBL17644101 | 0.82 | SLC6A2 (0.39) | LMNAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20971904 | 0.80 | HCAR3 (0.37) | KMT2AMEN1BLMLMNAMAPT | |
| SCHEMBL16579321 | 0.79 | MEN1 (0.50) | KMT2AMEN1BLMMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL20959290 | 0.77 | MEN1 (0.45) | KMT2AMEN1BLMGAAMAPT | |
| Hydrochloric Acid SCHEMBL20959291 | 0.77 | MEN1 (0.45) | KMT2AMEN1BLMGAAMAPT | |
| SCHEMBL25358540 | 0.75 | CYP2C19 (0.40) | HTTKDM4ESMN1; SMN2JAK3CYP2C19 | |
| SCHEMBL20971926 | 0.75 | CYP2C19 (0.40) | HTTKDM4ESMN1; SMN2JAK3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845729-B2 | Processes and intermediates in the preparation of C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11807609-B2 | Deuterated compounds as immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230008966-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2021-09-09 | — | — | US | disclosed |
| CN-113121415-A | Processes and intermediates for preparing C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-106999481-B | Processes and intermediates for preparing C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20200354320-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2020-11-12 | — | — | US | disclosed |
| EP-3703687-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | ChemoCentryx, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3682879-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3200791-B1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20190276402-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10266492-B2 | Processes and intermediates in the preparation of C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180072668-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9745268-B2 | Processes and intermediates in the preparation of C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3200791-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016053890-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20160090357-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807609-B2 | Deuterated compounds as immunomodulators | C3AR1, C5AR1, C5AR2 | KMT2A 4498/4885MEN1 839/4885BLM 3004/4885 |
| US-20180072668-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4726/4885MEN1 918/4885BLM 2095/4885 |
| US-20200354320-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4726/4885MEN1 918/4885BLM 2095/4885 |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | C3AR1, C5AR1, C5AR2 | KMT2A 4498/4885MEN1 839/4885BLM 3004/4885 |
| US-11845729-B2 | Processes and intermediates in the preparation of C5aR antagonists | C5AR1, C5AR2, C3AR1 | KMT2A 4726/4885MEN1 918/4885BLM 2095/4885 |
| US-20190276402-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4726/4885MEN1 918/4885BLM 2095/4885 |
| US-20230008966-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4726/4885MEN1 918/4885BLM 2095/4885 |
| US-10266492-B2 | Processes and intermediates in the preparation of C5aR antagonists | C5AR1, C5AR2, C3AR1 | KMT2A 4726/4885MEN1 918/4885BLM 2095/4885 |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | C3AR1, C5AR1, C5AR2 | KMT2A 4498/4885MEN1 839/4885BLM 3004/4885 |
| US-20160090357-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4726/4885MEN1 918/4885BLM 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.